Court Rules Against FDA, Reshaping Regenerative Medicine Regulation

LIBERTY, MO – March 27, 2026 – A federal court has delivered a landmark decision that stands to reshape the regulatory landscape for the burgeoning field of regenerative medicine. In a significant victory for Missouri-based Vitti Labs, a U.S. District Court Judge has ruled that the Food and Drug Administration's (FDA) narrow interpretation of criteria for human tissue products was "plainly erroneous," a move that could unlock new therapeutic innovations and expand patient access to treatment.

The ruling, issued on March 18 by Judge Brian C. Wimes of the U.S. District Court for the Western District of Missouri, granted Vitti Labs' motion for summary judgment in its lawsuit against the federal agency. The decision concludes a year-long legal battle centered on the definition of "minimal manipulation"—a critical regulatory standard that determines how human cell and tissue products (HCT/Ps) are brought to market.

The Heart of the Dispute: Defining "Minimal Manipulation"

At the core of the legal challenge is the FDA's framework for regulating HCT/Ps. These products, which range from skin grafts and bone allografts to novel therapies derived from umbilical cord tissue, are governed by a tiered system. Products deemed low-risk can be regulated solely under Section 361 of the Public Health Service (PHS) Act. This pathway is intended for products that are "minimally manipulated," intended for homologous use (performing the same basic function in the recipient as in the donor), and meet other specific criteria. This framework allows for faster access for patients and lower development costs compared to the rigorous pre-market approval process required for drugs and biologics under Section 351 of the Act.

The key point of contention was the FDA's interpretation of "minimal manipulation" for structural tissues like the umbilical cord. The agency's guidance stipulated that processing could not alter the tissue's "original relevant characteristics." The FDA took a restrictive stance, arguing that these characteristics should be defined only by the tissue's primary function in the original donor. In the case of an umbilical cord, the FDA asserted its only original relevant characteristic was its role as a conduit for blood between mother and fetus.

This narrow definition meant that if a company processed an umbilical cord to be used, for example, as a protective wound covering, the FDA could classify it as "more than minimally manipulated." Such a classification would force the product into the far more complex and costly regulatory pathway for new drugs, effectively stifling innovation and limiting the availability of such products.

A "Plainly Erroneous" Interpretation

In his decisive ruling, Judge Wimes dismantled the FDA's position. He declared the agency's interpretation, which focuses exclusively on the tissue's function in the donor, to be "plainly erroneous" and an "incorrect interpretation" of its own regulations.

Judge Wimes reasoned that the entire purpose of the regulatory system is patient-focused. "The entire regulatory scheme for HCT/P's revolves around sending safe products to patients, so it would not be logical to cut out consideration of recipients in the minimal manipulation analysis," the ruling states. This marks a fundamental shift from a donor-centric to a more holistic view that includes the product's intended benefit for the patient.

Critically, the court instructed the FDA to revise its approach. The agency must now "reconsider its conclusion consistent with the understanding that original relevant characteristics of structural tissue include the functions of the tissue in the donor that might aid a recipient." This directive forces the FDA to acknowledge that tissues like the umbilical cord possess multiple characteristics—such as providing structure, cushioning, and a matrix for cellular growth—that are relevant for therapeutic use in a patient, even if they were not the tissue's primary function in the donor.

A Victory for Vitti Labs and an Industry

For Vitti Labs, an AATB accredited and FDA registered tissue bank, the ruling is a validation of its year-long fight. The company had argued that the FDA's determination would have severely limited its ability to provide umbilical cord-based products under the Section 361 framework.

"Judge Wimes' decision is an important victory for Vitti Labs and the entire Section 361 HCT/P industry, and allowing patients to continue to be allowed access to wound grafts and other tissue-based products," said Philipp R. Vitti, the company's Chief Science Officer, in a statement. "We will continue to advocate and defend the proper interpretation of the Section 361 HCT/P 'minimal manipulation' criteria as the US Department of Health and Human Services intended it. This regulatory classification must be preserved in its entirety as it is critical for human tissue banking and organ donation to exist in the United States."

The decision provides much-needed clarity for dozens of other companies in the regenerative medicine space that develop and manufacture similar low-risk tissue products. By pushing back against the FDA's restrictive interpretation, the ruling may prevent a wave of reclassifications that could have removed numerous products from the market or made them prohibitively expensive.

Unlocking Innovation and Patient Access

The implications of the ruling extend far beyond corporate and legal circles, reaching directly to patients and healthcare providers. A broader, more flexible interpretation of "minimal manipulation" is expected to foster innovation rather than hinder it. Companies may now be more confident in investing in research and development for new tissue-based therapies, knowing a clearer and more reasonable regulatory pathway exists.

For patients, this could mean greater access to advanced treatments for a variety of conditions, particularly in areas like chronic wound care, orthopedic surgery, and sports medicine. Products derived from umbilical cord tissue, for instance, are rich in collagen, growth factors, and other components that can create a supportive environment for healing. By ensuring these products can remain under the more accessible Section 361 framework, the court's decision helps keep these promising therapies within reach for the patients who need them.

The ruling aligns the regulatory interpretation with the fundamental promise of regenerative medicine: using human tissues for reconstruction, repair, and replacement in a way that leverages their inherent biological properties to aid a recipient.

The FDA's Next Move

While Vitti Labs and its industry peers celebrate the victory, all eyes now turn to the FDA. The agency has been ordered to reconsider its position but has several potential courses of action. It could accept the court's ruling and begin the process of revising its official guidance documents to reflect a broader interpretation of "minimal manipulation." This would be the most direct path to resolving the regulatory uncertainty.

Alternatively, the FDA could choose to appeal Judge Wimes' decision to a higher court, which would prolong the legal battle and leave the industry in a state of limbo. The agency's response will be a critical indicator of its future posture toward the rapidly evolving field of regenerative medicine. For now, the court's decision serves as a powerful reminder of the judiciary's role in balancing regulatory oversight with the advancement of medical science.